Products
Technologies
Applications
Services
Resources
Selection Guides
About
Purified Anti-human CD22 Antibody
HIB22
HIB22 is an anti-human monoclonal antibody that recognizes the CD22 antigen. CD22 (also known as BL-CAM or Lyb8) is a 120 - 130 kD glycoprotein that is located on the surface of cells like B cells and stem cells. CD22 plays a role in essential cellular pathways, namely, the negative regulation of B cell receptor signaling pathway. Moreover, in many organisms, it is a negative regulator of calcium-mediated signaling, suppresses immunoglobulin secretion and is involved in the negative regulation of B cell receptor signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands like PI3-kinase, PLCg1, p53/56lyn and CD45. CD22 is a fairly uncommon antibody target, with a little more than 4000 publications in the last decade. Even still, CD22 is vital to cell biology research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography.
| Catalog | Size | Price | Quantity |
|---|---|---|---|
| 10220000 | 100 ug | Price |
Physical properties
| Molecular weight | N/A |
| Solvent | water |
Antibody properties
| Other names | BL-CAM; Siglec-2 |
| Clone | HIB22 |
| Host | mouse |
| Isotype | mouse IgG1 |
| Reactivity | human |
| Application | Flow Cytometry (FACS); ELISA; IHC; Western Blot |
Storage, safety and handling
| H-phrase | H303, H313, H333 |
| Hazard symbol | XN |
| Intended use | Research Use Only (RUO) |
| R-phrase | R20, R21, R22 |
| Storage | Refrigerated (2-8 °C); Minimize light exposure |
Contact us
| Telephone | |
| Fax | |
| sales@aatbio.com | |
| International | See distributors |
| Bulk request | Inquire |
| Custom size | Inquire |
| Technical Support | Contact us |
| Request quotation | Request |
| Purchase order | Send to sales@aatbio.com |
| Shipping | Standard overnight for United States, inquire for international |
Page updated on October 21, 2025